{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:09Z","timestamp":1793946549075,"version":"4.8.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Uppsala University","id":[{"id":"https:\/\/ror.org\/048a87296","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-ATH001 is an Affibody molecule targeting PDGFR\u03b2 in development as a Positron Emission Tomography (PET) tracer for non-invasive imaging of active fibrosis. Here we present first-in-human [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-ATH001 biodistribution and radiation dosimetry data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Radiation dosimetry of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-ATH001 was evaluated in healthy participants (n\u2009=\u20093) and participants with metabolic dysfunction-associated steatohepatitis (MASH) (n\u2009=\u20093). Each participant was intravenously administered\u2009~\u20092.5\u00a0MBq\/kg [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-ATH001 and imaged by whole-body PET for up to 3\u00a0h post-injection. Absorbed dose coefficients and effective doses according to ICRP 103 were calculated using IDAC DOSE 2.1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The effective dose of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-ATH001 was 0.028\u2009\u00b1\u20090.002\u00a0mSv\/MBq with kidneys as the dose-limiting organ. Administration of a target dose of 2\u00a0MBq\/kg would result in a sex-averaged effective dose of 4.1\u00a0mSv. Subjects tolerated the tracer administration well.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-ATH001 demonstrates a dosimetry and safety profile that supports further clinical development as a repeatable, non-invasive PET marker of active fibrosis in tissue.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08167-9","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:31:04Z","timestamp":1788845464000},"page":"8508-8513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biodistribution and radiation dosimetry of the PDGFR\u03b2 targeting PET tracer [68Ga]Ga-ATH001"],"prefix":"10.1007","volume":"53","author":[{"given":"Mark","family":"Lubberink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talakad G.","family":"Lohith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Derdak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wilkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Palm\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ramolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lodie","family":"Ferrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Mitran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Abouyzayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haakan","family":"Wennbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Rorsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vessby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-8790","authenticated-orcid":false,"given":"Olof","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"4","key":"8167_CR1","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","volume":"79","author":"CH Heldin","year":"1999","unstructured":"Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283\u2013316.","journal-title":"Physiol Rev"},{"issue":"2","key":"8167_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.32285","volume":"75","author":"SL Friedman","year":"2022","unstructured":"Friedman SL, Pinzani M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology. 2022;75(2):473\u201388. https:\/\/doi.org\/10.1002\/hep.32285.","journal-title":"Hepatology"},{"issue":"1","key":"8167_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s41181-025-00410-2","volume":"10","author":"CN Yashaswini","year":"2025","unstructured":"Yashaswini CN, Mitran B, Papadopoulos N, Wegrzyniak O, L\u00f6fblom J, Nordstr\u00f6m H, et al. PDGFR\u03b2 targeted Positron Emission Tomography as a non-invasive biomarker for activated Hepatic Stellate Cells: last steps before clinical translation. EJNMMI Radiopharm Chem. 2025;10(1):80.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"8167_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-023-00210-6","volume":"8","author":"O Wegrzyniak","year":"2023","unstructured":"Wegrzyniak O, Zhang B, Rokka J, et al. Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor \u03b2. EJNMMI Radiopharm Chem. 2023;8(1):23. https:\/\/doi.org\/10.1186\/s41181-023-00210-6.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"5","key":"8167_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109688","volume":"27","author":"O Wegrzyniak","year":"2024","unstructured":"Wegrzyniak O, Lechi F, Mitran B, et al. Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule. iScience. 2024;27(5):109688. https:\/\/doi.org\/10.1016\/j.isci.2024.109688.","journal-title":"iScience"},{"issue":"1","key":"8167_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-025-00366-3","volume":"10","author":"O Wegrzyniak","year":"2025","unstructured":"Wegrzyniak O, Lechi F, Rokka J, Mitran B, Zhang B, Thelander U, et al. PET imaging of platelet derived growth factor receptor \u03b2 in lung fibrosis. EJNMMI Radiopharm Chem. 2025;10(1):44. https:\/\/doi.org\/10.1186\/s41181-025-00366-3.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"8","key":"8167_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.stem.2026.07.003","volume":"33","author":"KH Grinnemo","year":"2026","unstructured":"Grinnemo KH, Braesch-Andersen K, Wedin JO, et al. Extracellular vesicle secretome from mesenchymal stromal cells prevents post-ischemic heart failure by targeting cardiac fibrosis. Cell Stem Cell. 2026;33(8):1324-1338.e10. https:\/\/doi.org\/10.1016\/j.stem.2026.07.003.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"8167_CR8","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/ph18121833","volume":"18","author":"I Velikyan","year":"2025","unstructured":"Velikyan I, Grinnemo KH, Flodin V, James S, Wagner M, Thelander U, et al. Ga-68 labelled affibody molecule based radiopharmaceutical targeting platelet derived growth factor receptor beta for detection of active fibrosis in patients with myocardial infarction. Pharmaceuticals (Basel). 2025;18(12):1833.","journal-title":"Pharmaceuticals (Basel)"},{"key":"8167_CR9","doi-asserted-by":"publisher","first-page":"109159","DOI":"10.1016\/j.nucmedbio.2025.109159","volume":"150\u2013151","author":"M Ferrat","year":"2025","unstructured":"Ferrat M, Moein MM, Eriksson O, Mitran B, Lohith TG, Jussing E, et al. GMP production of [68Ga]Ga-ATH001, a tracer targeting PDGFR\u03b2 for a microdose trial in humans. Nucl Med Biol. 2025;150\u2013151:109159.","journal-title":"Nucl Med Biol"},{"key":"8167_CR10","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06562361, accessed 27-DEC-2025."},{"issue":"1","key":"8167_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7(1):88. https:\/\/doi.org\/10.1186\/s13550-017-0339-3.","journal-title":"EJNMMI Res"},{"key":"8167_CR12","unstructured":"ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. Annals of the ICRP, 2007;37(2\u20134)."},{"issue":"2","key":"8167_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13502","volume":"6","author":"J S\u00f6rensen","year":"2016","unstructured":"S\u00f6rensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET\/CT. Theranostics. 2016;6(2):262\u201371. https:\/\/doi.org\/10.7150\/thno.13502.","journal-title":"Theranostics"},{"issue":"6","key":"8167_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.115.169342","volume":"57","author":"M Sandstr\u00f6m","year":"2016","unstructured":"Sandstr\u00f6m M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, et al. Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients. J Nucl Med. 2016;57(6):867\u201371. https:\/\/doi.org\/10.2967\/jnumed.115.169342.","journal-title":"J Nucl Med"},{"issue":"10","key":"8167_CR15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, Velikyan I, Garske-Rom\u00e1n U, S\u00f6rensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755\u20139. https:\/\/doi.org\/10.2967\/jnumed.113.120600.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08167-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:36Z","timestamp":1793672976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08167-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":15,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8167"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08167-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical PET imaging study was approved by the Swedish Ethical Review Authority as part of the Clinical Trials Information System (CTIS) approval 2023\u2013506555-15\u201300. All participants gave written informed consent before initiating any study procedures.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave informed consent to publication of clinical data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TGL, ZD, PW and HW are employees of Takeda Development Center Americas, Inc., and may hold company stocks. LJ is an employee and may hold stocks of Antaros Medical AB. AA and OE are employees of Antaros Tracer AB. OE is mentioned as inventor on a patent involving PDGFR\u03b2 binding peptides. BM was an employee of Antaros Medical AB at the time of the study. ML is a consultant of Antaros Tracer AB. The remaining authors have no disclosures to report.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}